Picture EBD Group World of Partnering Opportunities 650x100px
Document › Details

Life Sciences Partners (LSP). (3/18/21). "Press Release: LSP Announces Closing of Upsized $120 Million Nasdaq IPO of European Biotech Acquisition Corp (EBAC) Targeting European Biotech". Amsterdam.

Region Region United States (USA)
Organisation Organisation Nasdaq
  Group Nasdaq OMX (Group)
Products Product investment banking
  Product 2 BIOTECH
Index term Index term Life Sciences Partners–SEVERAL: investment, 202103 IPO $120m of SPAC European Biotech Acquisition Corp at Nasdaq
Person Person Kleijwegt, Martijn (Life Sciences Partners 200612 Managing Partner)



LSP, the leading European life sciences investor, today announces the closing of the upsized $120 million Nasdaq IPO of European Biotech Acquisition Corporation (EBAC). Eduardo Bravo will join LSP as a Partner and become EBAC’s CEO. LSP Founder and Managing Partner Martijn Kleijwegt will become EBAC’s Chairman and Mark Wegter will be joining EBAC’s Board of Directors. EBAC started trading on March 16, 2021 under the ticker symbol "EBACU".

Eduardo Bravo comments: “I am extremely happy to become part of LSP and join such a group of talented and professional people. I am convinced that with their unmatched access to European deal flow, their decades long track record of identifying the winners and my background as an experienced biotech entrepreneur who knows what it takes to run a successful biotech company, we are very well positioned to find the ideal target for EBAC. Many European biotech companies will be looking to list on Nasdaq in the months to come and EBAC provides a very attractive alternative route to such a direct listing.”

Martijn Kleijwegt added: “We are very proud to launch our SPAC and raise $120 million targeting European biotech. LSP has a track record of being first to market and we have done it again. We have seen the European life science market grow at an unprecedented pace over the past years. It is this growth that LSP, with its various investment strategies, has been capitalizing on. With Eduardo now joining our firm, taking direct responsibility to run EBAC, find a target and execute on a business combination, we have added further strength to our leading position in Europe.”

About EBAC: EBAC was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, re-organization, or similar business combination with one or more businesses. The Company intends to focus on identifying promising opportunities in the life sciences industry in Europe.

About Eduardo Bravo

Eduardo Bravo has over 25 years of senior management and board experience in the biopharmaceutical sector, having held the position of CEO at Nordic Nanovector, TiGenix and Cellerix. As CEO at TiGenix, he oversaw several financing rounds, the company’s IPO on Nasdaq and its eventual acquisition by Takeda. He is currently Chairman of the Board at Vivet Therapeutics and Engitix Ltd, and a Board Member at Sutura Therapeutics. Eduardo was President of the European Biopharmaceutical Enterprises Board of Directors between 2016 and 2018. He holds a degree in Business Administration and an MBA from INSEAD.

About LSP

LSP is one of the largest European investment firms providing financing for life sciences and health care companies. Since its inception in 1998, LSP’s management has raised $2.5 billion of risk capital targeting science, innovation, and – above all – a positive impact on society. LSP’s investment track record spans a 25-year period in which it has supported the growth of 300 companies, through private and public financings and through M&A. With offices in Amsterdam, Munich and Boston, LSP currently invests through five strategies, each having a distinctive investment scope and a dedicated team. LSP is an active contributor to the global life sciences industry and the European life science eco-system by assuming for-profit and not-for-profit roles as initiators, founders and board members in various private and public bodies and organizations. For more information, see

Record changed: 2023-06-05


Picture Sino Biological Symposium Antibody Engineering Leipzig 650x200px

More documents for Oculis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Sino Biological Symposium Antibody Engineering Leipzig 650x300px

» top